Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051797 | 1.00 | NPY5R (0.55) | NPY5RNOTUM | |
| Hydrochloric Acid SCHEMBL2888051 | 0.99 | NPY5R (0.54) | NPY5RNOTUM | |
| Hydrochloric Acid SCHEMBL7123289 | 0.99 | NPY5R (0.54) | NPY5RNOTUM | |
| SCHEMBL13563956 | 0.92 | NPY5R (0.50) | NPY5RNOTUM | |
| SCHEMBL30425441 | 0.89 | NOTUM (0.60) | NPY5RNOTUM | |
| SCHEMBL30051034 | 0.89 | NPY5R (0.52) | NPY5RNOTUM | |
| SCHEMBL31572868 | 0.86 | NOTUM (0.55) | NPY5RNOTUM | |
| SCHEMBL737327 | 0.86 | NPY5R (0.50) | NPY5RNOTUM | |
| SCHEMBL6216696 | 0.85 | NPY5R (0.52) | NPY5RNOTUM | |
| SCHEMBL6543355 | 0.85 | NPY5R (0.42) | NPY5RNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582715-B1 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2018-11-28 | — | — | EP | claimed |
| US-9315546-B2 | Growth hormone secretatogue receptor antagonists and uses thereof | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2016-04-19 | — | — | US | claimed |
| US-20130172242-A1 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | MCGILL UNIVERSITY (CA) | 2013-07-04 | — | — | US | claimed |
| EP-2582715-A2 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | The Administrators of the Tulane Educational Fund (US) | 2013-04-24 | — | — | EP | claimed |
| WO-2011159917-A2 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2011-12-22 | — | — | WO | claimed |
| US-20040220223-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2004-11-04 | — | — | US | claimed |
| US-20020049329-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2002-04-25 | — | — | US | claimed |
| US-6291672-B1 | FOR THE PREPARATION OF DRUGS USEFUL IN THERAPY OF PSYCHIATRIC DISEASES, DISEASES OF PSYCHOSOMATIC ORIGIN, HYPERTENSION | SANOFI-SYNTHELABO (FR) | 2001-09-18 | — | — | US | claimed |
| WO-2022228318-A1 | INDOLINE-CONTAINING SPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | 长春金赛药业有限责任公司 | 2022-11-03 | — | — | WO | disclosed |
| EP-3212201-B1 | NUCLEOSIDE KINASE INHIBITORS | BCI PHARMA (FR) | 2022-10-19 | — | — | EP | disclosed |
| EP-2582715-B1 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2018-11-28 | — | — | EP | disclosed |
| EP-3212201-A1 | NUCLEOSIDE KINASE INHIBITORS | BCI Pharma (FR) | 2017-09-06 | — | — | EP | disclosed |
| EP-2023924-B1 | ARYL-FUSED SPIROCYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2023924-B1 | ARYL-FUSED SPIROCYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2016-08-03 | — | — | EP | disclosed |
| WO-1998018762-A1 | NEW DERIVATIVES OF DIVERSELY SUBSTITUTED CYCLICAL AMIDE SELECTIVE ANTAGONISTS OF THE HUMAN RECEPTOR NK3, PROCESS FOR OBTAINING THEM, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1998-05-07 | — | — | WO | disclosed |
| WO-1998016527-A1 | BENZOXEPINE DERIVATIVES WHICH PROMOTE RELEASE OF GROWTH HORMONE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-04-23 | — | — | WO | disclosed |
| EP-0813414-A1 | COMBINATION OF BISPHOSPHONATES AND GROWTH HORMONE SECRETAGOGUES | MERCK & CO. INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| EP-0702681-A1 | SPIRO-SUBSTITUTED AZACYCLES AS NEUROKININ ANTAGONISTS | MERCK & CO. INC. (US) | 1996-03-27 | — | — | EP | disclosed |
| WO-1994029309-A1 | SPIRO-SUBSTITUTED AZACYCLES AS NEUROKININ ANTAGONISTS | MERCK & CO., INC. (US) | 1994-12-22 | — | — | WO | disclosed |
| WO-1994013696-A1 | SPIRO PIPERIDINES AND HOMOLOGS WHICH PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220223-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | TACR2, BDKRB2, ACKR3 | NPY5R 589/4885NOTUM 4655/4885 |
| US-20020049329-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | TACR2, BDKRB2, ACKR3 | NPY5R 589/4885NOTUM 4655/4885 |
| US-20130172242-A1 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | GHSR, GHRHR, GIPR | NPY5R 27/4885NOTUM 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.